Department of Renal Medicine, Salford Royal NHS Foundation Trust, Stott Lane, Salford, M6 8HD, UK.
Division of Cardiovascular Sciences, University of Manchester, Manchester, M13 9PL, UK.
BMC Nephrol. 2021 Mar 6;22(1):82. doi: 10.1186/s12882-021-02282-5.
Patients with rapidly declining renal function face the dual threat of end-stage renal disease (ESRD) and mortality prior to ESRD. What is less well characterised is whether the pattern of the renal trajectory, linear or non-linear, unmasks subgroups of rapidly progressing patients that face adverse outcomes in a differential manner.
An individual eGFR slope was applied to all outpatient estimated glomerular filtration rate (eGFR) values for each patient in the Salford Kidney Study from 2002 to 2018 who had at least 2 years follow-up, ≥4 eGFR values and baseline eGFR 15 to < 60 ml/min/1.73m. Rapid progression was defined as an annual eGFR slope of ≤ - 3 ml/min/1.73m/yr and patients were categorised as linear or non-linear progressors based on the nature of their eGFR-time graphs. A Fine-Gray competing risk hazard model was used to determine factors associated with progression to ESRD and with mortality prior to ESRD. Cumulative incidence function curves highlighted differences in outcomes between linear and non-linear patients.
There were 211 rapidly deteriorating patients with linear eGFR trajectories and 61 rapid non-linear patients in the study cohort. Factors associated with ESRD included younger age, male gender, lower baseline eGFR and higher serum phosphate, whilst older age, history of myocardial infarction and anaemia predicted mortality prior to ESRD. Over a median follow-up of 3.7 years, linear progressors reached ESRD sooner whilst those with non-linear progression faced significantly higher rates of mortality prior to ESRD.
Patients with rapid eGFR decline have high rates of adverse outcomes that are differentially expressed in those progressing linearly and non-linearly as a result of differing phenotypic profiles. Consequently, addressing individual risk factor profiles is important to deliver optimal personalised patient care.
肾功能迅速下降的患者在进入终末期肾病(ESRD)之前,同时面临 ESRD 和死亡的双重威胁。但目前人们对肾功能轨迹的模式(线性或非线性)是否能揭示出以不同方式面临不良结局的快速进展患者亚组,还了解甚少。
本研究将 Salford Kidney Study 中 2002 年至 2018 年间至少随访 2 年、至少有 4 次 eGFR 值且基线 eGFR 为 15-<60ml/min/1.73m 的患者的所有门诊估算肾小球滤过率(eGFR)值应用个体 eGFR 斜率进行分析。将每年 eGFR 斜率≤-3ml/min/1.73m/yr 定义为快速进展,根据 eGFR-时间图的性质将患者分为线性或非线性进展者。采用 Fine-Gray 竞争风险风险模型来确定与进展为 ESRD 和 ESRD 之前死亡相关的因素。累积发生率函数曲线突出了线性和非线性患者之间结局的差异。
在研究队列中,有 211 例线性 eGFR 轨迹的快速恶化患者和 61 例快速非线性患者。与 ESRD 相关的因素包括年龄较小、男性、较低的基线 eGFR 和较高的血清磷酸盐,而年龄较大、心肌梗死和贫血病史则与 ESRD 之前的死亡率相关。在中位数为 3.7 年的随访中,线性进展者更早达到 ESRD,而非线性进展者在 ESRD 之前的死亡率明显更高。
肾功能快速下降的患者不良结局发生率较高,这些患者在以线性和非线性方式进展时表现出不同的表型特征,其结局表达也不同。因此,针对个体的危险因素特征进行处理对于提供最佳的个性化患者护理非常重要。